After moving on from his position as the CEO of Aegerion Pharmaceuticals, Marc Beer is now looking to the future. The 45-year-old businessman, co-founder, chairman and CEO of Renovia recently announced that the company has managed to secure a deal with another company which will provide them with $32 million to help their startup along with another $10 million in venture debt. This new deal will help this fledgling company to move forward with several products they’re currently producing that are designed to help females with pelvic floor disorders such as urinary incontinence and the occasional urinary tract infection. The Longwood fund was one of the companies that was instrumental in ensuring that this deal actually came to fruition.
This is Beer’s first big business deal since leaving Aegerion back in 2015 and now he is looking to turn his life around by pushing this deal through and helping women all over the world who suffer from various types of pelvic disorders. The Medtech company currently based out of Boston, Massachusetts is dedicated to treating these types of disorders which scientists estimate affects over a quarter of a billion women throughout the world. This new funding will go toward further testing and development of these products. In a recent statement, Marc Beer expressed his excitement about this new business deal and talked about how this will impact their future.
Marc Beer currently has over 25 years of experience in the pharmaceutical and biotech industry and he first founded Renovia over a year ago. Around the turn of the 21st century, Beer became the founder and CEO of a company known as Viacell, a biotech company that focuses on developing and preserving the stem cells that come from the umbilical cord. In just seven years, he led the company and helped it achieve exponential growth until it eventually merged with a company known as Perkin Elmer back in 2007. He first enrolled at Miami University in the fall of 1983 and earned a Bachelor of Science in business administration in the spring of 1987.
He has served in other roles as well. While serving as the founder and CEO of Viacell, he was also serving on the board of directors for a company known as Erytech Pharma, a well-renowned and highly respected biopharmaceutical corporation. He has also served in various different capacities within a company known as Genzyme. At one point, he was even the Vice President of Global Marketing, a role in which he was responsible for launching several different products that help to treat rare conditions and diseases. So we wish him the best of luck in his future and hope he has success with his new startup company. Learn more: https://www.linkedin.com/in/marcbeer